Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
JAZZ Jazz Pharmaceuticals plc
- Stocks
- Healthcare
- NASDAQ: JAZZ
Price (delayed)
$109.55
Market cap
$6.75B
P/E Ratio
14.06
Dividend/share
N/A
EPS
$7.79
Enterprise value
$10.3B
Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration
Highlights
Jazz Pharmaceuticals's equity has increased by 13% YoY
The company's debt fell by 12% QoQ and by 6% YoY
Jazz Pharmaceuticals's quick ratio has soared by 63% YoY but it has decreased by 26% from the previous quarter
The company's EPS rose by 49% YoY but it fell by 14% QoQ
Key stats
What are the main financial stats of JAZZ
Market
Valuations
Earnings
Shares outstanding
61.63M
Market cap
$6.75B
Enterprise value
$10.3B
Price to earnings (P/E)
14.06
Price to book (P/B)
1.59
Price to sales (P/S)
1.64
EV/EBIT
17.54
EV/EBITDA
8.25
EV/Sales
2.53
Revenue
$4.06B
Gross profit
$3.61B
Operating income
$594.53M
Net income
$482.2M
EBIT
$586.97M
EBITDA
$1.25B
Free cash flow
$1.51B
Per share
Balance sheet
Liquidity
EPS
$7.79
EPS diluted
$7.41
Free cash flow per share
$24.82
Book value per share
$68.74
Revenue per share
$66.66
TBVPS
$82.92
Total assets
$11.53B
Total liabilities
$7.36B
Debt
$5.41B
Equity
$4.17B
Working capital
$2.91B
Debt to equity
1.29
Current ratio
3.38
Quick ratio
2.64
Net debt/EBITDA
2.84
Margins
Efficiency
Dividend
EBITDA margin
30.7%
Gross margin
88.8%
Net margin
11.9%
Operating margin
14.6%
Return on assets
4.1%
Return on equity
11.9%
Return on invested capital
7.5%
Return on capital employed
5.7%
Return on sales
14.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JAZZ stock price
How has the Jazz Pharmaceuticals stock price performed over time
Intraday
-1.32%
1 week
2.78%
1 month
9.18%
1 year
2.41%
YTD
-11.04%
QTD
-11.76%
Financial performance
How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$4.06B
Gross profit
$3.61B
Operating income
$594.53M
Net income
$482.2M
Gross margin
88.8%
Net margin
11.9%
Jazz Pharmaceuticals's net income has increased by 46% YoY but it has decreased by 14% QoQ
The company's net margin rose by 38% YoY but it fell by 14% QoQ
JAZZ's operating margin is down by 17% since the previous quarter but it is up by 8% year-on-year
The operating income has declined by 17% since the previous quarter but it rose by 15% year-on-year
Price vs fundamentals
How does JAZZ's price correlate with its fundamentals
Growth
What is Jazz Pharmaceuticals's growth rate over time
Valuation
What is Jazz Pharmaceuticals stock price valuation
P/E
14.06
P/B
1.59
P/S
1.64
EV/EBIT
17.54
EV/EBITDA
8.25
EV/Sales
2.53
The company's EPS rose by 49% YoY but it fell by 14% QoQ
The P/E is 7% lower than the last 4 quarters average of 15.4
The price to book (P/B) is 30% lower than the 5-year quarterly average of 2.3 and 10% lower than the last 4 quarters average of 1.8
Jazz Pharmaceuticals's equity has increased by 13% YoY
The price to sales (P/S) is 36% less than the 5-year quarterly average of 2.6 and 7% less than the last 4 quarters average of 1.8
The revenue has grown by 6% YoY
Efficiency
How efficient is Jazz Pharmaceuticals business performance
The company's return on assets rose by 41% YoY but it fell by 15% QoQ
The return on equity has increased by 29% year-on-year but it has declined by 16% since the previous quarter
JAZZ's ROIC is down by 18% QoQ but it is up by 2.7% YoY
The company's return on sales fell by 17% QoQ but it rose by 7% YoY
Dividends
What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JAZZ.
Financial health
How did Jazz Pharmaceuticals financials performed over time
The total assets is 57% greater than the total liabilities
Jazz Pharmaceuticals's quick ratio has soared by 63% YoY but it has decreased by 26% from the previous quarter
The company's current ratio rose by 49% YoY but it fell by 24% QoQ
The company's debt is 29% higher than its equity
Jazz Pharmaceuticals's debt to equity has decreased by 17% YoY and by 14% QoQ
Jazz Pharmaceuticals's equity has increased by 13% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.